Loading…
Myelin oligodendrocyte glycoprotein (MOG35-55) induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice
Multiple sclerosis is a chronic neuroinflammatory demyelinating disorder of the central nervous system with a strong neurodegenerative component. While the exact etiology of the disease is yet unclear, autoreactive T lymphocytes are thought to play a central role in its pathophysiology. MS therapy i...
Saved in:
Published in: | Journal of visualized experiments 2014-04 (86) |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c485t-9281ff62195cb6a8e1ace7f42f57be45372c233b8658c486d87305717f40c7be3 |
---|---|
cites | |
container_end_page | |
container_issue | 86 |
container_start_page | |
container_title | Journal of visualized experiments |
container_volume | |
creator | Bittner, Stefan Afzali, Ali M Wiendl, Heinz Meuth, Sven G |
description | Multiple sclerosis is a chronic neuroinflammatory demyelinating disorder of the central nervous system with a strong neurodegenerative component. While the exact etiology of the disease is yet unclear, autoreactive T lymphocytes are thought to play a central role in its pathophysiology. MS therapy is only partially effective so far and research efforts continue to expand our knowledge on the pathophysiology of the disease and to develop novel treatment strategies. Experimental autoimmune encephalomyelitis (EAE) is the most common animal model for MS sharing many clinical and pathophysiological features. There is a broad diversity of EAE models which reflect different clinical, immunological and histological aspects of human MS. Actively-induced EAE in mice is the easiest inducible model with robust and replicable results. It is especially suited for investigating the effects of drugs or of particular genes by using transgenic mice challenged by autoimmune neuroinflammation. Therefore, mice are immunized with CNS homogenates or peptides of myelin proteins. Due to the low immunogenic potential of these peptides, strong adjuvants are used. EAE susceptibility and phenotype depends on the chosen antigen and rodent strain. C57BL/6 mice are the commonly used strain for transgenic mouse construction and respond among others to myelin oligodendrocyte glycoprotein (MOG). The immunogenic epitope MOG35-55 is suspended in complete Freund's adjuvant (CFA) prior to immunization and pertussis toxin is applied on the day of immunization and two days later. Mice develop a "classic" self-limited monophasic EAE with ascending flaccid paralysis within 9-14 days after immunization. Mice are evaluated daily using a clinical scoring system for 25-50 days. Special considerations for care taking of animals with EAE as well as potential applications and limitations of this model are discussed. |
doi_str_mv | 10.3791/51275 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4172026</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1618148630</sourcerecordid><originalsourceid>FETCH-LOGICAL-c485t-9281ff62195cb6a8e1ace7f42f57be45372c233b8658c486d87305717f40c7be3</originalsourceid><addsrcrecordid>eNqFkUtP6zAQhS0EAi7wF5A3SGUR8COOnQ0SVL1cpCI2ILGzXGdSjJw4xElF_z3u5SFYsZqR5pszZ3QQOqLkjMuSngvKpNhC-7TMSUaUfNz-1u-hPzE-E1IwItQu2mO5LCVlYh-tbtfgXYuDd8tQQVv1wa4HwEu_tqHrwwBpOLm9u-YiE-IUu7YaLVQYXjvoXQPtYDw24xBc04wtYGgtdE_Gh2ajO7iIJ7PL2WYPT4W8mp8XuHEWDtFObXyEo496gB7-zu6n_7L53fXN9HKe2VyJISuZonVdMFoKuyiMAmosyDpntZALyAWXzDLOF6oQKm0UlZKcCEkTQmwi-AG6eNftxkUDlU1-e-N1l6ybfq2DcfrnpHVPehlWOqeSEVYkgcmHQB9eRoiDbly04L1pIYxR04Iqmi5z8jsq0h-UpQwSevKO2j7E2EP95YgSvYlT_48zccff7X9Rn_nxNwo-mWE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1521912620</pqid></control><display><type>article</type><title>Myelin oligodendrocyte glycoprotein (MOG35-55) induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice</title><source>PubMed Central</source><creator>Bittner, Stefan ; Afzali, Ali M ; Wiendl, Heinz ; Meuth, Sven G</creator><creatorcontrib>Bittner, Stefan ; Afzali, Ali M ; Wiendl, Heinz ; Meuth, Sven G</creatorcontrib><description>Multiple sclerosis is a chronic neuroinflammatory demyelinating disorder of the central nervous system with a strong neurodegenerative component. While the exact etiology of the disease is yet unclear, autoreactive T lymphocytes are thought to play a central role in its pathophysiology. MS therapy is only partially effective so far and research efforts continue to expand our knowledge on the pathophysiology of the disease and to develop novel treatment strategies. Experimental autoimmune encephalomyelitis (EAE) is the most common animal model for MS sharing many clinical and pathophysiological features. There is a broad diversity of EAE models which reflect different clinical, immunological and histological aspects of human MS. Actively-induced EAE in mice is the easiest inducible model with robust and replicable results. It is especially suited for investigating the effects of drugs or of particular genes by using transgenic mice challenged by autoimmune neuroinflammation. Therefore, mice are immunized with CNS homogenates or peptides of myelin proteins. Due to the low immunogenic potential of these peptides, strong adjuvants are used. EAE susceptibility and phenotype depends on the chosen antigen and rodent strain. C57BL/6 mice are the commonly used strain for transgenic mouse construction and respond among others to myelin oligodendrocyte glycoprotein (MOG). The immunogenic epitope MOG35-55 is suspended in complete Freund's adjuvant (CFA) prior to immunization and pertussis toxin is applied on the day of immunization and two days later. Mice develop a "classic" self-limited monophasic EAE with ascending flaccid paralysis within 9-14 days after immunization. Mice are evaluated daily using a clinical scoring system for 25-50 days. Special considerations for care taking of animals with EAE as well as potential applications and limitations of this model are discussed.</description><identifier>ISSN: 1940-087X</identifier><identifier>EISSN: 1940-087X</identifier><identifier>DOI: 10.3791/51275</identifier><identifier>PMID: 24797125</identifier><language>eng</language><publisher>United States: MyJove Corporation</publisher><subject>Animals ; Encephalomyelitis, Autoimmune, Experimental - etiology ; Encephalomyelitis, Autoimmune, Experimental - immunology ; Female ; Immunology ; Mice ; Mice, Inbred C57BL ; Myelin-Oligodendrocyte Glycoprotein - administration & dosage ; Myelin-Oligodendrocyte Glycoprotein - immunology ; Peptide Fragments - administration & dosage ; Peptide Fragments - immunology</subject><ispartof>Journal of visualized experiments, 2014-04 (86)</ispartof><rights>Copyright © 2014, Journal of Visualized Experiments 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c485t-9281ff62195cb6a8e1ace7f42f57be45372c233b8658c486d87305717f40c7be3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172026/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172026/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24797125$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bittner, Stefan</creatorcontrib><creatorcontrib>Afzali, Ali M</creatorcontrib><creatorcontrib>Wiendl, Heinz</creatorcontrib><creatorcontrib>Meuth, Sven G</creatorcontrib><title>Myelin oligodendrocyte glycoprotein (MOG35-55) induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice</title><title>Journal of visualized experiments</title><addtitle>J Vis Exp</addtitle><description>Multiple sclerosis is a chronic neuroinflammatory demyelinating disorder of the central nervous system with a strong neurodegenerative component. While the exact etiology of the disease is yet unclear, autoreactive T lymphocytes are thought to play a central role in its pathophysiology. MS therapy is only partially effective so far and research efforts continue to expand our knowledge on the pathophysiology of the disease and to develop novel treatment strategies. Experimental autoimmune encephalomyelitis (EAE) is the most common animal model for MS sharing many clinical and pathophysiological features. There is a broad diversity of EAE models which reflect different clinical, immunological and histological aspects of human MS. Actively-induced EAE in mice is the easiest inducible model with robust and replicable results. It is especially suited for investigating the effects of drugs or of particular genes by using transgenic mice challenged by autoimmune neuroinflammation. Therefore, mice are immunized with CNS homogenates or peptides of myelin proteins. Due to the low immunogenic potential of these peptides, strong adjuvants are used. EAE susceptibility and phenotype depends on the chosen antigen and rodent strain. C57BL/6 mice are the commonly used strain for transgenic mouse construction and respond among others to myelin oligodendrocyte glycoprotein (MOG). The immunogenic epitope MOG35-55 is suspended in complete Freund's adjuvant (CFA) prior to immunization and pertussis toxin is applied on the day of immunization and two days later. Mice develop a "classic" self-limited monophasic EAE with ascending flaccid paralysis within 9-14 days after immunization. Mice are evaluated daily using a clinical scoring system for 25-50 days. Special considerations for care taking of animals with EAE as well as potential applications and limitations of this model are discussed.</description><subject>Animals</subject><subject>Encephalomyelitis, Autoimmune, Experimental - etiology</subject><subject>Encephalomyelitis, Autoimmune, Experimental - immunology</subject><subject>Female</subject><subject>Immunology</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Myelin-Oligodendrocyte Glycoprotein - administration & dosage</subject><subject>Myelin-Oligodendrocyte Glycoprotein - immunology</subject><subject>Peptide Fragments - administration & dosage</subject><subject>Peptide Fragments - immunology</subject><issn>1940-087X</issn><issn>1940-087X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNqFkUtP6zAQhS0EAi7wF5A3SGUR8COOnQ0SVL1cpCI2ILGzXGdSjJw4xElF_z3u5SFYsZqR5pszZ3QQOqLkjMuSngvKpNhC-7TMSUaUfNz-1u-hPzE-E1IwItQu2mO5LCVlYh-tbtfgXYuDd8tQQVv1wa4HwEu_tqHrwwBpOLm9u-YiE-IUu7YaLVQYXjvoXQPtYDw24xBc04wtYGgtdE_Gh2ajO7iIJ7PL2WYPT4W8mp8XuHEWDtFObXyEo496gB7-zu6n_7L53fXN9HKe2VyJISuZonVdMFoKuyiMAmosyDpntZALyAWXzDLOF6oQKm0UlZKcCEkTQmwi-AG6eNftxkUDlU1-e-N1l6ybfq2DcfrnpHVPehlWOqeSEVYkgcmHQB9eRoiDbly04L1pIYxR04Iqmi5z8jsq0h-UpQwSevKO2j7E2EP95YgSvYlT_48zccff7X9Rn_nxNwo-mWE</recordid><startdate>20140415</startdate><enddate>20140415</enddate><creator>Bittner, Stefan</creator><creator>Afzali, Ali M</creator><creator>Wiendl, Heinz</creator><creator>Meuth, Sven G</creator><general>MyJove Corporation</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20140415</creationdate><title>Myelin oligodendrocyte glycoprotein (MOG35-55) induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice</title><author>Bittner, Stefan ; Afzali, Ali M ; Wiendl, Heinz ; Meuth, Sven G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c485t-9281ff62195cb6a8e1ace7f42f57be45372c233b8658c486d87305717f40c7be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Encephalomyelitis, Autoimmune, Experimental - etiology</topic><topic>Encephalomyelitis, Autoimmune, Experimental - immunology</topic><topic>Female</topic><topic>Immunology</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Myelin-Oligodendrocyte Glycoprotein - administration & dosage</topic><topic>Myelin-Oligodendrocyte Glycoprotein - immunology</topic><topic>Peptide Fragments - administration & dosage</topic><topic>Peptide Fragments - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bittner, Stefan</creatorcontrib><creatorcontrib>Afzali, Ali M</creatorcontrib><creatorcontrib>Wiendl, Heinz</creatorcontrib><creatorcontrib>Meuth, Sven G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of visualized experiments</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bittner, Stefan</au><au>Afzali, Ali M</au><au>Wiendl, Heinz</au><au>Meuth, Sven G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Myelin oligodendrocyte glycoprotein (MOG35-55) induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice</atitle><jtitle>Journal of visualized experiments</jtitle><addtitle>J Vis Exp</addtitle><date>2014-04-15</date><risdate>2014</risdate><issue>86</issue><issn>1940-087X</issn><eissn>1940-087X</eissn><abstract>Multiple sclerosis is a chronic neuroinflammatory demyelinating disorder of the central nervous system with a strong neurodegenerative component. While the exact etiology of the disease is yet unclear, autoreactive T lymphocytes are thought to play a central role in its pathophysiology. MS therapy is only partially effective so far and research efforts continue to expand our knowledge on the pathophysiology of the disease and to develop novel treatment strategies. Experimental autoimmune encephalomyelitis (EAE) is the most common animal model for MS sharing many clinical and pathophysiological features. There is a broad diversity of EAE models which reflect different clinical, immunological and histological aspects of human MS. Actively-induced EAE in mice is the easiest inducible model with robust and replicable results. It is especially suited for investigating the effects of drugs or of particular genes by using transgenic mice challenged by autoimmune neuroinflammation. Therefore, mice are immunized with CNS homogenates or peptides of myelin proteins. Due to the low immunogenic potential of these peptides, strong adjuvants are used. EAE susceptibility and phenotype depends on the chosen antigen and rodent strain. C57BL/6 mice are the commonly used strain for transgenic mouse construction and respond among others to myelin oligodendrocyte glycoprotein (MOG). The immunogenic epitope MOG35-55 is suspended in complete Freund's adjuvant (CFA) prior to immunization and pertussis toxin is applied on the day of immunization and two days later. Mice develop a "classic" self-limited monophasic EAE with ascending flaccid paralysis within 9-14 days after immunization. Mice are evaluated daily using a clinical scoring system for 25-50 days. Special considerations for care taking of animals with EAE as well as potential applications and limitations of this model are discussed.</abstract><cop>United States</cop><pub>MyJove Corporation</pub><pmid>24797125</pmid><doi>10.3791/51275</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1940-087X |
ispartof | Journal of visualized experiments, 2014-04 (86) |
issn | 1940-087X 1940-087X |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4172026 |
source | PubMed Central |
subjects | Animals Encephalomyelitis, Autoimmune, Experimental - etiology Encephalomyelitis, Autoimmune, Experimental - immunology Female Immunology Mice Mice, Inbred C57BL Myelin-Oligodendrocyte Glycoprotein - administration & dosage Myelin-Oligodendrocyte Glycoprotein - immunology Peptide Fragments - administration & dosage Peptide Fragments - immunology |
title | Myelin oligodendrocyte glycoprotein (MOG35-55) induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T16%3A35%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Myelin%20oligodendrocyte%20glycoprotein%20(MOG35-55)%20induced%20experimental%20autoimmune%20encephalomyelitis%20(EAE)%20in%20C57BL/6%20mice&rft.jtitle=Journal%20of%20visualized%20experiments&rft.au=Bittner,%20Stefan&rft.date=2014-04-15&rft.issue=86&rft.issn=1940-087X&rft.eissn=1940-087X&rft_id=info:doi/10.3791/51275&rft_dat=%3Cproquest_pubme%3E1618148630%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c485t-9281ff62195cb6a8e1ace7f42f57be45372c233b8658c486d87305717f40c7be3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1521912620&rft_id=info:pmid/24797125&rfr_iscdi=true |